Literature DB >> 23334506

Appropriateness of hydroxyethylcellulose gel as a placebo control in vaginal microbicide trials: a comparison of the two control arms of HPTN 035.

Barbra A Richardson1, Cliff Kelly, Gita Ramjee, Thomas Fleming, Bonus Makanani, Sarah Roberts, Petina Musara, Nkhafwire Mkandawire, Thomas Moench, Anne Coletti, Lydia Soto-Torres, Salim A Karim.   

Abstract

OBJECTIVE: To compare the 2 control arms of HPTN 035 [a hydroxyethylcellulose (HEC) gel control arm and a no-gel control arm] to assess the behavioral effects associated with gel use and direct causal effects of the HEC gel on sexually transmitted infections (STIs), pregnancy, and genital safety.
DESIGN: Randomized trial with 1 blinded (HEC gel) and 1 open-label (no-gel) control arms.
METHODS: HIV-uninfected, sexually active women were randomized into the HEC gel arm (n = 771) and into the no-gel arm (n = 772) in 5 countries. Participants in the HEC gel arm were instructed to insert the study gel intravaginally <1 hour before each vaginal sex act. Data on sexual behavior, adherence, safety, pregnancy, and STIs were collected quarterly for 12-30 months of follow-up.
RESULTS: During follow-up, mean reported condom use in the past week was significantly higher in the no-gel arm (81% versus 70%, P < 0.001). There were no significant differences, after adjusting for this differential condom use, between the 2 arms in the rates of genital safety events, pregnancy outcomes, or STIs, including HIV-1.
CONCLUSIONS: In this large randomized trial, we found no significant differences between the no-gel and HEC gel arms in the rates of genital safety events, pregnancy outcomes, or STIs. These results aid interpretation of the results of previous vaginal microbicide trials that used the HEC gel as a control. The HEC gel is suitable as a control for ongoing and future vaginal microbicide studies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23334506      PMCID: PMC3625489          DOI: 10.1097/QAI.0b013e31828607c5

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  20 in total

1.  Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.

Authors:  Quarraisha Abdool Karim; Salim S Abdool Karim; Janet A Frohlich; Anneke C Grobler; Cheryl Baxter; Leila E Mansoor; Ayesha B M Kharsany; Sengeziwe Sibeko; Koleka P Mlisana; Zaheen Omar; Tanuja N Gengiah; Silvia Maarschalk; Natasha Arulappan; Mukelisiwe Mlotshwa; Lynn Morris; Douglas Taylor
Journal:  Science       Date:  2010-07-19       Impact factor: 47.728

2.  In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials.

Authors:  Deborah Tien; Roger L Schnaare; Feirong Kang; Gina Cohl; Timothy J McCormick; Thomas R Moench; Gustavo Doncel; Karen Watson; Robert W Buckheit; Mark G Lewis; Jill Schwartz; Karen Douville; Joseph W Romano
Journal:  AIDS Res Hum Retroviruses       Date:  2005-10       Impact factor: 2.205

3.  Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial.

Authors:  Lut Van Damme; Gita Ramjee; Michel Alary; Bea Vuylsteke; Verapol Chandeying; Helen Rees; Pachara Sirivongrangson; Léonard Mukenge-Tshibaka; Virginie Ettiègne-Traoré; Charn Uaheowitchai; Salim S Abdool Karim; Benoît Mâsse; Jos Perriëns; Marie Laga
Journal:  Lancet       Date:  2002-09-28       Impact factor: 79.321

4.  Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women.

Authors:  Salim S Abdool Karim; Barbra A Richardson; Gita Ramjee; Irving F Hoffman; Zvavahera M Chirenje; Taha Taha; Muzala Kapina; Lisa Maslankowski; Anne Coletti; Albert Profy; Thomas R Moench; Estelle Piwowar-Manning; Benoît Mâsse; Sharon L Hillier; Lydia Soto-Torres
Journal:  AIDS       Date:  2011-04-24       Impact factor: 4.177

5.  Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission.

Authors:  Lut Van Damme; Roshini Govinden; Florence M Mirembe; Fernand Guédou; Suniti Solomon; Marissa L Becker; B S Pradeep; A K Krishnan; Michel Alary; Bina Pande; Gita Ramjee; Jennifer Deese; Tania Crucitti; Doug Taylor
Journal:  N Engl J Med       Date:  2008-07-31       Impact factor: 91.245

6.  Some design issues in trials of microbicides for the prevention of HIV infection.

Authors:  Thomas R Fleming; Barbra A Richardson
Journal:  J Infect Dis       Date:  2004-07-20       Impact factor: 5.226

7.  The use of the diaphragm instead of condoms in a phase III diaphragm trial.

Authors:  Ariane van der Straten; Helen Cheng; Jie Moore; Deborah Kacanek; Kelly Blanchard; Guy De Bruyn; Gita Ramjee; Tsungai Chipato; Elizabeth T Montgomery; Nancy Padian
Journal:  AIDS Behav       Date:  2008-12-16

8.  WHO/CONRAD technical consultation on nonoxynol-9, World Health Organization, Geneva, 9-10 October 2001: summary report.

Authors: 
Journal:  Reprod Health Matters       Date:  2002-11

9.  The diaphragm and lubricant gel for prevention of cervical sexually transmitted infections: results of a randomized controlled trial.

Authors:  Gita Ramjee; Ariane van der Straten; Tsungai Chipato; Guy de Bruyn; Kelly Blanchard; Stephen Shiboski; Helen Cheng; Elizabeth Montgomery; Nancy Padian
Journal:  PLoS One       Date:  2008-10-22       Impact factor: 3.240

10.  SAVVY (C31G) gel for prevention of HIV infection in women: a Phase 3, double-blind, randomized, placebo-controlled trial in Ghana.

Authors:  Leigh Peterson; Kavita Nanda; Baafuor Kofi Opoku; William Kwabena Ampofo; Margaret Owusu-Amoako; Andrew Yiadom Boakye; Wes Rountree; Amanda Troxler; Rosalie Dominik; Ronald Roddy; Laneta Dorflinger
Journal:  PLoS One       Date:  2007-12-19       Impact factor: 3.240

View more
  11 in total

1.  In vitro and in vivo evaluation of two carrageenan-based formulations to prevent HPV acquisition.

Authors:  Aixa Rodríguez; Kyle Kleinbeck; Olga Mizenina; Larisa Kizima; Keith Levendosky; Ninochka Jean-Pierre; Guillermo Villegas; Brian E Ford; Michael L Cooney; Natalia Teleshova; Melissa Robbiani; Betsy C Herold; Thomas Zydowsky; José A Fernández Romero
Journal:  Antiviral Res       Date:  2014-06-05       Impact factor: 5.970

2.  Tenofovir Gel for Prevention of Herpes Simplex Virus Type 2 Acquisition: Findings From the VOICE Trial.

Authors:  Jeanne M Marrazzo; Lorna Rabe; Cliff Kelly; Barbra Richardson; Carolyn Deal; Jill L Schwartz; Z M Chirenje; Jeanna Piper; Rhoda Ashley Morrow; Craig W Hendrix; Mark A Marzinke; Sharon L Hillier
Journal:  J Infect Dis       Date:  2019-05-24       Impact factor: 5.226

3.  Evaluation of Vaginal Drug Levels and Safety of a Locally Administered Glycerol Monolaurate Cream in Rhesus Macaques.

Authors:  Ameya R Kirtane; Meghan K Rothenberger; Abby Frieberg; Karla Nephew; Nancy Schultz-Darken; Thomas Schmidt; Thomas Reimann; Ashley T Haase; Jayanth Panyam
Journal:  J Pharm Sci       Date:  2017-04-04       Impact factor: 3.534

4.  Sexual frequency and pain in a randomized clinical trial of vaginal estradiol tablets, moisturizer, and placebo in postmenopausal women.

Authors:  Caroline M Mitchell; Katherine A Guthrie; Joseph Larson; Susan Diem; Andrea Z LaCroix; Bette Caan; Jan L Shifren; Nancy F Woods; Julia R Heiman; Stacy T Lindau; Susan D Reed
Journal:  Menopause       Date:  2019-08       Impact factor: 2.953

5.  Tenofovir-based preexposure prophylaxis for HIV infection among African women.

Authors:  Jeanne M Marrazzo; Gita Ramjee; Barbra A Richardson; Kailazarid Gomez; Nyaradzo Mgodi; Gonasagrie Nair; Thesla Palanee; Clemensia Nakabiito; Ariane van der Straten; Lisa Noguchi; Craig W Hendrix; James Y Dai; Shayhana Ganesh; Baningi Mkhize; Marthinette Taljaard; Urvi M Parikh; Jeanna Piper; Benoît Mâsse; Cynthia Grossman; James Rooney; Jill L Schwartz; Heather Watts; Mark A Marzinke; Sharon L Hillier; Ian M McGowan; Z Mike Chirenje
Journal:  N Engl J Med       Date:  2015-02-05       Impact factor: 91.245

6.  Efficacy of Vaginal Estradiol or Vaginal Moisturizer vs Placebo for Treating Postmenopausal Vulvovaginal Symptoms: A Randomized Clinical Trial.

Authors:  Caroline M Mitchell; Susan D Reed; Susan Diem; Joseph C Larson; Katherine M Newton; Kristine E Ensrud; Andrea Z LaCroix; Bette Caan; Katherine A Guthrie
Journal:  JAMA Intern Med       Date:  2018-05-01       Impact factor: 21.873

7.  HPTN 035 phase II/IIb randomised safety and effectiveness study of the vaginal microbicides BufferGel and 0.5% PRO 2000 for the prevention of sexually transmitted infections in women.

Authors:  M Bradford Guffey; Barbra Richardson; Marla Husnik; Bonus Makanani; David Chilongozi; Elmer Yu; Gita Ramjee; Nyaradzo Mgodi; Kailazarid Gomez; Sharon L Hillier; Salim Abdool Karim
Journal:  Sex Transm Infect       Date:  2014-06-04       Impact factor: 3.519

Review 8.  HIV prevention trial design in an era of effective pre-exposure prophylaxis.

Authors:  Amy Cutrell; Deborah Donnell; David T Dunn; David V Glidden; Anneke Grobler; Brett Hanscom; Britt S Stancil; R Daniel Meyer; Ronnie Wang; Robert L Cuffe
Journal:  HIV Clin Trials       Date:  2017-10-17

9.  Unexpected Inflammatory Effects of Intravaginal Gels (Universal Placebo Gel and Nonoxynol-9) on the Upper Female Reproductive Tract: A Randomized Crossover Study.

Authors:  Karen Smith-McCune; Joseph C Chen; Ruth M Greenblatt; Uma Shanmugasundaram; Barbara L Shacklett; Joan F Hilton; Brittni Johnson; Juan C Irwin; Linda C Giudice
Journal:  PLoS One       Date:  2015-07-15       Impact factor: 3.240

10.  Impact of the griffithsin anti-HIV microbicide and placebo gels on the rectal mucosal proteome and microbiome in non-human primates.

Authors:  Lauren Girard; Kenzie Birse; Johanna B Holm; Pawel Gajer; Mike S Humphrys; David Garber; Patricia Guenthner; Laura Noël-Romas; Max Abou; Stuart McCorrister; Garrett Westmacott; Lin Wang; Lisa C Rohan; Nobuyuki Matoba; Janet McNicholl; Kenneth E Palmer; Jacques Ravel; Adam D Burgener
Journal:  Sci Rep       Date:  2018-05-23       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.